Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Expert Charts the Changing Treatment Landscape in CRPC

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Switch Maintenance Darolutamide Prolongs rPFS in Metastatic Prostate Cancer

Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung Cancer

FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Expert Charts the Changing Treatment Landscape in CRPC

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Switch Maintenance Darolutamide Prolongs rPFS in Metastatic Prostate Cancer

Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung Cancer

FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Expert Charts the Changing Treatment Landscape in CRPC

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Switch Maintenance Darolutamide Prolongs rPFS in Metastatic Prostate Cancer

Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung Cancer

FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer

Related Content

Use of a kit that prepares for gallium Ga 68 gozetotide injection in the phase 3 VISION study affirms its ability to identify patients who suitable to receive PSMA-based radioligand for metastatic prostate cancer.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Use of a kit that prepares for gallium Ga 68 gozetotide injection in the phase 3 VISION study affirms its ability to identify patients who suitable to receive PSMA-based radioligand for metastatic prostate cancer.

Expert Charts the Changing Treatment Landscape in CRPC

Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Matthew Dallos, MD, discusses current challenges in the treatment of castration-resistant prostate cancer and the potential of antibody-drug conjugates in this disease space.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Matthew Dallos, MD, discusses current challenges in the treatment of castration-resistant prostate cancer and the potential of antibody-drug conjugates in this disease space.

Switch Maintenance Darolutamide Prolongs rPFS in Metastatic Prostate Cancer

Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Data from a phase 2 placebo-controlled trial may support darolutamide switch maintenance therapy following at least 1 androgen receptor pathway inhibitor and taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.

Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung Cancer

Data from a phase 2 placebo-controlled trial may support darolutamide switch maintenance therapy following at least 1 androgen receptor pathway inhibitor and taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.

Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.